i
News
News · 2026-11-17

Isomorphic Labs raises $5 billion in second mega-round in six months

Dataist Dataist

Alphabet has invested in Isomorphic Labs as part of a $5 billion round — the company’s second multibillion-dollar raise in six months. Greenoaks and Sequoia Capital co-led the round, joined by new investor Andreessen Horowitz, Alphabet and all existing investors. The money will go toward developing the company’s IsoDDE platform and advancing drug candidates toward clinical trials.

Cover: Isomorphic Labs raises $5 billion in second mega-round in six months

Platform and drug development

In May 2026, Isomorphic Labs raised $2.1 billion. Founded in 2021, the company is developing IsoDDE, the Isomorphic Drug Design Engine. The company says the system goes beyond AlphaFold 3 and is designed to predict more accurately how drugs bind to targets and where they interact.

Isomorphic Labs works with Novartis, Eli Lilly and Johnson & Johnson. The company does not yet have an approved drug.

$5 billionnew round
$2.1 billionMay 2026 round

Leadership and the AlphaFold team

Isomorphic Labs is led by Demis Hassabis. In August 2026, he stepped back from day-to-day leadership of Google DeepMind and became Alphabet’s chief scientist. In 2024, Hassabis and John Jumper received the Nobel Prize in Chemistry for their work on AlphaFold.

In July 2026, DeepMind disbanded the original AlphaFold team. Many researchers moved to Isomorphic Labs or took on other projects, while nearly a quarter left DeepMind. In early November 2026, however, the company released AlphaGenome 2: a model that predicts how DNA variants affect gene activity in specific cell types.

Dataist's take: The new round will allow Isomorphic Labs to keep developing its platform and preparing drug candidates for clinical trials. But the company still has no approved drug, so the funding does not yet mean its work has reached patients.

Daily AI news

Every day we pick what actually matters in AI and explain it plainly — no hype, no filler. Subscribe if you want to follow where the industry is going.

Only what matters — every day

Follow on X